These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12893358)

  • 21. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [First line indications for hormonal therapy in prostate cancer].
    Boccon-Gibod L; Richaud P; Coloby P; Coulange C; Culine S; Davin JL; Soulié M; Zerbib M
    Prog Urol; 2010 Feb; 20(2):109-15. PubMed ID: 20142051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant.
    Marks LS
    Urology; 2003 Dec; 62(6 Suppl 1):36-42. PubMed ID: 14706507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BNCT for recurrent intracranial meningeal tumours - case reports.
    Stenstam BH; Pellettieri L; Sorteberg W; Rezaei A; Sköld K
    Acta Neurol Scand; 2007 Apr; 115(4):243-7. PubMed ID: 17376121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
    Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
    Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is there effective systemic therapy for recurrent surgery- and radiation-refractory meningioma?
    Chamberlain MC
    CNS Oncol; 2013 Jan; 2(1):1-5. PubMed ID: 25054350
    [No Abstract]   [Full Text] [Related]  

  • 27. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.
    Grossfeld GD; Small EJ; Carroll PR
    Urology; 1998 Jan; 51(1):137-44. PubMed ID: 9457309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging association between androgen deprivation therapy and male meningioma: significant expression of luteinizing hormone-releasing hormone receptor in male meningioma.
    Li Q; Coulson H; Klaassen Z; Sharma S; Ramalingam P; Moses KA; Terris MK
    Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):387-90. PubMed ID: 24100643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hormonal treatment in biochemical recurrence after radical prostatectomy].
    Antolín AR; Ojeda JM; Otero JR; Rodríguez AC; Castellano D; Esteban MD; Sicilia LD; González RD
    Arch Esp Urol; 2012; 65(1):111-21. PubMed ID: 22318183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer.
    Uehara S; Yuasa T; Fujii Y; Yano A; Yamamoto S; Masuda H; Fukui I; Yonese J
    BMC Res Notes; 2015 Aug; 8():335. PubMed ID: 26242866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Post-radiation dedifferentiation of meningioma into chondroblastic osteosarcoma].
    Svajdler M; Bohus P; Rychlý B; Sulla I; Moram M
    Cesk Patol; 2009 Jan; 45(1):20-3. PubMed ID: 19402318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgical resection and permanent brachytherapy for recurrent atypical and malignant meningioma.
    Ware ML; Larson DA; Sneed PK; Wara WW; McDermott MW
    Neurosurgery; 2004 Jan; 54(1):55-63; discussion 63-4. PubMed ID: 14683541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radical treatment strategies improve the long-term outcome of recurrent atypical meningiomas.
    Li F; Lai ZP; Lin JK; Zhu G; Feng H
    Chin Med J (Engl); 2011 Aug; 124(15):2387-91. PubMed ID: 22029080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radical prostatectomy for clinically localized prostate cancer in patients aged 75 years or older: comparison with primary androgen deprivation therapy.
    Ryu JH; Kim SJ; Kim YB; Jung TY; Ko WJ; Kim SI; Kim DY; Oh TH; Moon KT; Cho HJ; Cho JM; Yoo TK
    Aging Male; 2018 Mar; 21(1):17-23. PubMed ID: 28828908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
    Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
    Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
    Hoda MR; Kramer MW; Merseburger AS; Cronauer MV
    Expert Opin Pharmacother; 2017 Jan; 18(1):105-113. PubMed ID: 27826989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?
    Krahn M; Bremner KE; Tomlinson G; Luo J; Ritvo P; Naglie G; Alibhai SM
    BJU Int; 2011 Nov; 108(10):1588-96. PubMed ID: 21453344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence-based medicine: comparative analysis of luteinizing hormone-releasing hormone analogues in combination with external beam radiation and surgery in the treatment of carcinoma of the prostate.
    González SV; Pijuan XM
    BJU Int; 2011 Apr; 107(8):1200-8. PubMed ID: 21078049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.